You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
Budget impact model for IXA-001 in resistant hypertension. Features population funnel analysis, uptake scenarios, secondary HTN etiology stratification, and interactive Streamlit dashboard with Excel exports.
Cost-effectiveness microsimulation model for IXA-001 (aldosterone synthase inhibitor) vs Spironolactone in resistant hypertension. Features dual-branch phenotyping, PA risk modifiers, AF tracking, and interactive Streamlit dashboard.
economic analysis: Reproducible Markov cost-effectiveness model- cariprazine vs risperidone for schizophrenia with predominant negative symptoms | Submitted to Value in Health 2026 | under review